18
Participants
Start Date
May 25, 2025
Primary Completion Date
May 25, 2027
Study Completion Date
June 25, 2027
Dual-targeting BCMA-CD19 CAR-T cell infusion
Approximately 3-5 days prior to BCMA-CD19 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
Shanghai Liquan Hospital
OTHER
Beijing GoBroad Hospital
OTHER